Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
about
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotypeDecreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV.Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentationPartial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphomaLoss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classificationLack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphomaFOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrRole of gene methylation in antitumor immune response: implication for tumor progression.Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation.Construction and analysis of tree models for chromosomal classification of diffuse large B-cell lymphomas.A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma
P2860
Q33632104-7A133259-5D81-4DDF-A235-E57626D5EE5FQ34032232-A3A640E9-0AFD-4158-8509-1C30515F435AQ34334683-518DE197-FA78-457A-8EF8-0312DA4A9B6DQ35189915-93249C98-9A53-4C1C-B3C9-20375F669C87Q35776418-1FFDC50F-C942-463C-8CA4-6D616E50772FQ35849831-52B2DA59-8D04-4E01-8985-175A133E4D15Q36118020-1528EBCA-10AB-45AE-8776-91DB194F4101Q36280547-639AE542-F687-4931-9659-E6C0EAF31397Q36366994-01658FE9-C794-4EF5-8E33-E6AA6DD28A20Q36650112-9800DCE6-30A4-4C48-8FDB-9F17E6512E8CQ36946744-E2DAC646-5849-43A1-A416-46E1AE57E363Q37006876-A2F3FA6B-7E0C-4754-917F-1090A80CCDC5Q37132658-E95C1543-9282-41A8-823D-225131031164Q37910910-C790D38D-3ABA-44A8-A1D9-70C4990E47CAQ38344066-E0BE69F9-6C9F-4449-BBC7-4704A13D49DDQ39136897-DC19E3FF-44D8-43E5-8950-79A4D8B5FB27Q39492021-AAA85291-375E-4C69-B2B3-7DE687E1C91AQ41050317-3C486A91-D377-42E1-9581-8A03130243AEQ41652576-65D91F9F-79B7-4F78-B508-285D588C0686Q41704739-037F766C-3426-4AA4-A0FA-B92E29BCC107Q41974323-69801E73-84C5-4F5C-92F8-C206FED359F7Q47562297-8AEF1C53-2A94-4F9D-A8B6-FC3678077536Q48197020-1EEBE501-5F08-41E7-85D1-784034154D83Q58690185-147B4268-7890-4AF5-8921-C9FA64F9EBC9
P2860
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Loss of major histocompatibili ...... due to chromosomal deletions.
@ast
Loss of major histocompatibili ...... due to chromosomal deletions.
@en
type
label
Loss of major histocompatibili ...... due to chromosomal deletions.
@ast
Loss of major histocompatibili ...... due to chromosomal deletions.
@en
prefLabel
Loss of major histocompatibili ...... due to chromosomal deletions.
@ast
Loss of major histocompatibili ...... due to chromosomal deletions.
@en
P2093
P2860
P50
P1433
P1476
Loss of major histocompatibili ...... t due to chromosomal deletions
@en
P2093
Andreas Rosenwald
Andreas Zettl
Elaine S Jaffe
German Ott
H Konrad Muller-Hermelink
Joseph M Unger
Lisa M Rimsza
Louis M Staudt
Michael Leblanc
Richard I Fisher
P2860
P304
P356
10.1182/BLOOD-2005-04-1510
P407
P50
P577
2005-10-20T00:00:00Z